Jpmorgan Chase & CO Pear Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$0.21 - $1.24 $11,192 - $66,088	53,297 Added 23687.56%	53,522 $13,000
Q1 2023 May 11, 2023	SELL	$0.21 - $1.24 $8,145 - $48,099	-38,790 Reduced 99.42%	225 $0
Q4 2022 Feb 13, 2023	BUY	$0.99 - $2.91 $1,846 - $5,427	1,865 Added 5.02%	39,015 $46,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $2.27 $7,126 - $124,439	-54,819 Reduced 59.61%	37,150 $76,000
Q2 2022 Aug 11, 2022	BUY	$1.54 - $6.48 $139,476 - $586,887	90,569 Added 6469.21%	91,969 $142,000
Q1 2022 May 11, 2022	BUY	$3.67 - $7.63 $5,138 - $10,682	1,400 New	1,400 $7,000

23M

Ticker PEAR
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 138,768,992
Market Cap $1.39M
Description
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a softwa...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.